Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer NSCLC whose tumors expressed high levels of PD-1 with Keytrudapembrolizumab is superior to standar [...]

Flu Shot 101 – What You Need to Know

Flu season is here again and besides a fever and runny nose it can bring about the longtime controversy surrounding vaccines In order to protect more human lives this year and to clarify some of the most common misconceptions surrounding the flu vaccine t [...]

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma

The US Food and Drug Administration today granted accelerated approval to Aliqopa copanlisib for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies For patients with relaps [...]

Imfinzi Improves Survival in Stage 3 Non Small Cell Lung Cancer

Immunotherapy could be the new standard of care in patients with non-small cell lung cancer NSCLC The novel immunotherapy checkpoint inhibitors Keytrudapembrolizumab and Opdivo nivolumab are already standard of care for advanced NSCLC1 A recently publishe [...]

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients receive [...]

Immunotherapy Active Against Triple-Negative Breast Cancer

October is breast cancer awareness month and patients with triple-negative breast cancer TNBC should be aware that data from two clinical trials provide additional evidence that they may derive benefit from checkpoint inhibitor therapy1-4 About Triple Neg [...]

LynparzaTM Slows Spread of Inherited Breast Cancer Caused By BRCA Mutations

LynparzaTM olaparib a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes also appears to slowe the progression of breast cancer caused in part by mutations in the BRCA gene BRCA is an inherited condition that ca [...]

FDA approves new treatment for certain advanced or metastatic breast cancers

The US Food and Drug Administration today approved Verzenio abemaciclib to treat adult patients who have hormone receptor HR-positive human epidermal growth factor receptor 2 HER2-negative advanced or metastatic breast cancer that has progressed after tak [...]

FDA Approves Aliqopa for Relapsed Follicular Lymphoma

The US Food and Drug Administration FDA granted accelerated approval to Aliqopa copanlisib an intravenously administered pan-class I phosphatidylinositol 3-kinase PI3K inhibitor for the treatment of adults with relapsed follicular lymphoma who have receiv [...]

New Standard of Care for Treatment of Resectable Gastric Cancer

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid1 Survival in resectabl [...]